This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This study furthers the research of previous studies (MT2003-01 and MT2004-25) which were to determine whether a specific preparatory regimen (clyclophosphamide and fludarabine) could create an environment in which infused NK cells can grow and effectively treat patients with relapsed AML. This study will test the NK cells with a fully myeloblative preparative regimen (similar to our myeloblative cord blood protocol MT2005-10). We are specifically studying whether standard UCB myeloblative preparatory regimen can be successfully combined with an infusion of cord blood NK cells and NK cell precursor cells.
Showing the most recent 10 out of 724 publications